Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2012 Drug Launches Suggest Reasons For Optimism

Executive Summary

Launches in 2012 clearly reflect the changes in pharma’s R&D investment priorities in recent years, as the industry has shifted emphasis from primary-care blockbusters to more targeted specialty models. The group includes potential blockbusters like Xeljanz, a dozen novel oncologics, the first new obesity drug in over a decade, and several treatments for rare diseases.

You may also be interested in...



Early Drug Launches Off To a Strong Start So Far in 2013

2012 was a record year for drug approvals; now many of those drugs approved last year and this year are launching and off to a strong start in the first three months of 2013.

Many New Oncology Drugs In 2012, With Prices That Test The Limits

More than a dozen new molecular entities launched for the treatment of cancer in 2012, advancing care for seriously ill people, but many carry price tags of $100,000 per year or more for treatment, escalating debate over cost of care and how best to direct limited healthcare resources.

Eliquis Label Looks Great, But May Leave Door Open For Pradaxa To Compete On Efficacy

Bristol/Pfizer’s Eliquis secures an attractive FDA label for atrial fibrillation on three key fronts: superior stroke prevention, reduced major bleeding and reduced all-cause mortality. With its superiority in preventing hemorrhagic strokes, Eliquis has the clear lead in terms of safety. But Boehringer’s competing Pradaxa remains the only new oral anticoagulant with proven superiority for preventing purely ischemic strokes, which is the main goal of atrial fibrillation treatment.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055053

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel